{
    "clinical_study": {
        "@rank": "67210", 
        "acronym": "ICY", 
        "arm_group": {
            "arm_group_label": "RMIs", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "For patients who are suffering from hepatocellular carcinoma and are treated with\n      radioembolization, the purpose of this study is to analyse parameters of functional MRIs\n      that are modified early and to detect parameters that vary significantly after treatment."
        }, 
        "brief_title": "Interest of Functional MRI (Magnetic Resonance Imagery) (in Patients Suffering From Hepatocellular Carcinoma and Treated With Yttrium", 
        "condition": "Hepatocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Stress, Psychological", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Early, intermediate, advanced, non metastatic Hepatocellular Carcinoma. Indication\n             for radioembolization validated after pluridisciplinary committee meeting.\n\n          -  Isolated target on initial imagery (invasive hepatocellular carcinoma   excluded)\n\n          -  WHO (World Health organization) Performance status: 0, 1 or 2\n\n          -  If cirrhosis, Child A score with total bilirubin less than 30 micromoles per liter\n\n          -  Creatinine clearance more or equal to 30 mL/min\n\n          -  Patient informed and consent signature obtained\n\n        Exclusion Criteria:\n\n          -  Invasive hepatocellular carcinoma without any isolated tumor\n\n          -  Disease needing 2 injections of Therasphere\n\n          -  Thrombosis extending into the porta(thrombosis of one of left or right branch\n             authorized), extra hepatic metastasis\n\n          -  Previous treatment by chemoembolization, radiofrequency less than 3 months before\n             radioembolization\n\n          -  No antiangiogenic concomitant treatment, 15 days before and 15 days after\n             radioembolization, including Sorafenib\n\n          -  Associated disease which could prevent patient from receiving treatment\n\n          -  RMI contre-indication(particle or metal prosthesis, pacemaker, claustrophobia) or\n             contrast product contre-indication (allergy)\n\n          -  Patient already participating in an other therapeutic trial with an experimental drug\n\n          -  Pregnant or childbearing potential women or breastfeeding women\n\n          -  minors, persons deprived of liberty or protected adults (maintenance of justice,\n             guardianship or supervision) Unable to comply with trial medical follow-up for\n             geographical, social or psychological reasons\n\n          -  Unable to sign an informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02003339", 
            "org_study_id": "2012-JE-CHC-Pron", 
            "secondary_id": "2012-A00972-41"
        }, 
        "intervention": {
            "arm_group_label": "RMIs", 
            "intervention_name": "Additional RMIs", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 2, 2013", 
        "location": {
            "contact": {
                "email": "j.edeline@rennes.unicancer.fr", 
                "last_name": "Julien EDELINE, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Rennes", 
                    "country": "France", 
                    "zip": "35042"
                }, 
                "name": "Centre Eug\u00e8ne Marquis"
            }, 
            "investigator": {
                "last_name": "Julien EDELINE, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Prospective Study on Interest of Functional MRI in Early Assessment of Radioembolization Efficiency in Patients Suffering From Hepatocellular Carcinoma", 
        "overall_contact": {
            "email": "j.edeline@rennes.unicancer.fr", 
            "last_name": "Julien EDELINE, MD"
        }, 
        "overall_official": {
            "affiliation": "Centre Eug\u00e8ne Marquis", 
            "last_name": "Julien EDELINE, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Modifications of functional MRI parameters", 
            "safety_issue": "No", 
            "time_frame": "Before radioembolization and up to 6 months after radioembolization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02003339"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Correlation between functional MRIs parameters and tumoral response", 
                "safety_issue": "No", 
                "time_frame": "Measured 6 months after radioembolization"
            }, 
            {
                "measure": "Assessment of alternative morphological response criteria : EASL (European Association for study of the liver)  and mRECIST (m response evaluation criteria in solid tumor) criteria. Link with RECIST response.", 
                "safety_issue": "No", 
                "time_frame": "2 and 6 months"
            }, 
            {
                "measure": "Change of VEGF (vascular endothelial growth factor) release", 
                "safety_issue": "No", 
                "time_frame": "From day 0 to 2 months"
            }
        ], 
        "source": "Center Eugene Marquis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Center Eugene Marquis", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}